Rescue of Major Histocompatibility-DR Surface Expression in Retinoblastoma-Defective, Non-small Cell Lung Carcinoma Cells by the MS-275 Histone Deacetylase Inhibitor-Reference-Cited by-同舟云学术

Rescue of Major Histocompatibility-DR Surface Expression in Retinoblastoma-Defective, Non-small Cell Lung Carcinoma Cells by the MS-275 Histone Deacetylase Inhibitor

Published:2009 Issue:3 Volume:32 Page:480-482
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Niesen Melissa Ihla¹,Blanck George¹

Affiliation:

1. Department of Molecular Medicine, College of Medicine, University of South Florida

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

http://www.jstage.jst.go.jp/article/bpb/32/3/32_3_480/_pdf

Reference12 articles.

1. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity

2. Killing of Rat Adenocarcinoma 13762in Situby Adoptive Transfer of CD4+Anti-tumor T Cells Requires Tumor Expression of Cell Surface MHC Class II Molecules

3. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

4. Pathologic expression of MHC class II is driven by mitogen-activated protein kinases

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetics approach in cancer treatment with focus on lung and breast cancer;Cancer Epigenetics and Nanomedicine;2024

2. Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma;Progress in Retinal and Eye Research;2021-12

3. Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy;Clinical Cancer Research;2019-10-23

Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment

;OncoTargets and Therapy;2019-09

5. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy;Cancer Immunology, Immunotherapy;2017-11-09